Trial Profile

A Clinical Study to Evaluate AU-011 as a Single Agent and as a Combination Therapy in Solid tumors

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 12 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belzupacap sarotalocan (Primary) ; Antineoplastics
Indications Solid tumours
Focus Adverse reactions; Proof of concept
Sponsors Aura Biosciences

Most Recent Events

13 Nov 2025 According to the Aura Biosciences media release, Company is planning to initiate a Phase 1 proof-of-concept trial and on track to report with early proof of concept data from Australian clinical sites expected in 2026.
15 Apr 2021 New trial record
14 Apr 2021 According to an Aura Biosciences media release, AU-011 is expected to enter the clinic for the treatment of solid tumors in 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com